期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 18, 期 2, 页码 462-466出版社
WILEY
DOI: 10.1111/ajt.14498
关键词
allergy; antibiotic prophylaxis; clinical research; practice; desensitization; drug toxicity; infectious disease; kidney transplantation; nephrology; kidney transplantation: living donor
资金
- National Health and Medical Research Council
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER
While trimethoprim-sulfamethoxazole is considered first-line therapy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug reactions may limit use and increase reliance on costly and less effective alternatives, often aerosolized pentamidine. We report our experience implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to optimize prophylaxis in this patient cohort. We retrospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis prior to and after protocol implementation. Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or during the prophylaxis period, of which 83% were non-immune-mediated and 17% were immune-mediated. Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol implementation (4/22 vs 23/27; P=.0001), with no recurrence of adverse drug reactions in 74%. In those who experienced a new or recurrent reaction (26%), all were mild and self-limiting with only 1 recurrence of an immune-mediated reaction. After protocol implementation, aerosolized pentamidine-associated costs were reduced. The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context of both prior immune and non-immune-mediated reactions was safe and successful in improving the uptake of first-line Pneumocystis pneumonia prophylaxis in renal transplant recipients. The authors describe the development and implementation of a protocol for trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge in renal transplant recipients, and report a safe increase in first-line Pneumocystis pneumonia prophylaxis and reduction in costs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据